Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Parallel Group, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of a Single Subcutaneous Injection of RG-101 Combined with Oral GSK2878175 Taken Once Daily for 6, 9, or 12 Weeks in Treatment Naïve, Genotype 1 and 3, Chronic Hepatitis C Patients

Next Previous
Trial Profile

A Multi-Center, Parallel Group, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of a Single Subcutaneous Injection of RG-101 Combined with Oral GSK2878175 Taken Once Daily for 6, 9, or 12 Weeks in Treatment Naïve, Genotype 1 and 3, Chronic Hepatitis C Patients

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 2878175 (Primary) ; RG 101 (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Regulus Therapeutics

Most Recent Events

  • 09 Oct 2017 This trial has been completed in Greece according to European Clinical Trials Database record.
  • 08 Sep 2017 This trial has been completed in Hungary according to European Clinical Trials Database record.
  • 25 Jan 2017 According to a Regulus Therapeutics media release, the FDA has requested the final safety and efficacy data from on-going RG-101 trials for reconsidering of the clinical hold on RG-101 program. Data will be available after completion of 48 weeks of follow up, anticipated in the fourth quarter 2017.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top